If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
“ ...and will be the go to Vaccine, but that been known for over 6 months, as it started work on Second Generation Vaccine in September and started in phase 3 Trial in January, but is trailed in the EU, South Africa and Latin America.“
That’s factually incorrect. The phase 3 trial has nothing to do with variant vaccine but for 1st gen vaccine. The UK gov has indeed ordered 50M of the 2nd gen (multi-valent) vaccine, which as of now hasn’t entered clinical trials.
I own GSK, not CVAC.
Hi all, has the filter function for chat here stopped working?
Fed up with one of the pretender of this club member. ;)
https://www.mirror.co.uk/3am/celebrity-news/club-7-now-penniless-racism-23584781?utm_source=sharebar&utm_medium=email&utm_campaign=sharebar
"In February 2021 CureVac and the British pharmaceutical company GlaxoSmithKline (GSK) agreed to jointly develop next-generation ***multi-valent mRNA vaccines against COVID-19***. The development of new vaccine candidates is strengthened by a partnership with the UK Government and its Vaccines Taskforce, which CureVac also entered in February 2021."
Ray, this can be found at the bottom of CVAC press releases. The only clue is multi-valent.
Thanks for sharing that Ray. That chunky doc looks like CureVac current trial?
It is an mRNA vaccine but the vaccine design doesn't incorporate N-protein antigen. This P3 trial isn't complete yet.
The UK gov order is for the CureVac next generation variant vaccine --- for which they'll need to start a new trial. My feeling overall is our CT's are more complex to design but not outside our scientific capabilities.
The fact that the government has secured an order just shows UK government handling of this crisis (probably close to 500M vaccine doses ordered in total just by UK). You need to wait for Scancell + consortium to make some announcements first about this, trials etc. It's a little known company, not a 4B mcap.
I agree wholeheartedly. What's more interesting for me is how the parallel between 'cold tumors' and immune escape phenomena in Sars-Cov2 esp with the later variants/lineage. The novel mRNA vaccines group show how cancer immunotherapy tech lead the way in providing first gen vaccines for the world (Biontech, Moderna etc). Perhaps Lindy et al will provide some insight into the immune escape mechanism and potential solution using one or a combination of our platforms. Too far-fetched?
Hi Konar, I think it's to do with partnerships and the emphasis in the plural. It's unlikely that one big partner will sort out the trials, manufacturing and commercialisation of our vaccine. The clinical trials will also need to be big enough and therefore we need many academic collaborators. If we aim to have Scancell vaccine by 2022, we need to get the timeline right from the beginning! and don't we need help with that (I say that in a nice way).
It'll be interesting to see who will ultimately lead this. The Oxford/AZN vaccines have at least 7-8 collaborators -- and I won't pretend to know what they each bring to the table. As the UK gov will likely to want some part in this, they may facilitate (for want of a better word) this process too. Maybe I'm too optimistic but my view is the gov hasn't gone far enough.
Kashdog,
Curevac P3 trial is for first gen vaccine and in collab with Bayer and CEPI. Most likely in German/EU base.
Their collab with GSK is for "variant vaccine" as per the press release last month. That will be manufactured in UK and UK gov has ordered 50M of 2nd gen vaccine. Trials have not started. Thanks.
https://www.curevac.com/en/2021/02/05/curevac-and-uk-government-to-collaborate-on-development-of-vaccines-against-sars-cov-2-variants/
https://www.biopharma-reporter.com/Article/2021/02/08/CureVac-sets-out-broad-pipeline-of-first-and-second-generation-COVID-19-vaccines
I think the Brazil variant was also detected in Faroe Island. I'm sure there's no direct flight from Manaus to there - most likely 2-3 transits. UK quarantine measures combined with track and trace are notoriously inadequate. I don't like the news to be fair.
Interesting that he mentions us in the same para as the Curevac next gen vaccine (50m orders from UK gov when no trial has started). All focus should be on starting the Covidity trial -- by comparison BionNTech diverted 600 staff to work on their vaccine. All credit to Prof Sahin. It's a monumental task but we have the fund to pay for P1 trial and the teams in Nottingham unis. Vaccine orders will start coming. It's in the UK interest to see Scancell succeed.
My opinion is that P1 will start v soon with or without partner. Cash is more than enough for P1. Likelihood is we’re going to have back-to-back trials P1-2,2-3 and it’s a given that we will need partners. plural. With money and manufacturing capacity.
Gates Foundation is an attractive funder and a big Pharma that’ll be willing to produce the vaccine at-risk.
The race has already started for 2nd gen vaccines and were not first off the starting line. I remain a buyer at this level.
Hasiba, sorry it’s me again. I just read Berm’s original message in the thread and your last reply. Obviously the T cells don’t go “into the cells” to do the clean up. I just feel the need to reply because high avidity T cells is what our offering is all about.
Once one receives the vaccine and our cells produce the antigens (S- and N- proteins or their fragment) and present them on the surface, T helper cells detect and raise the alarm so that the whole immune system work in concert after that. When a vaccinated cell dies, it’ll trigger a cascade — APC, T- and B- acting in concert. The neutralising antibodies then do the clearing up/prevent other cells from being infected. Whether this is magic/science it’s at the crux of it.
I know you’re looking for the clinical correlation but surely that’s just a matter of time. But I’m also trying to look at it in reverse — when people stopped getting fatigue / relapsing symptoms especially following the vaccine, what’s happening inside them. More antibody studies are being published and we can look at the specific cohorts.
Anyway, if you don’t find this useful, I hope others will! Thanks Berm for starting the discussion and I agree with others — one of our most consistent and well-respected poster here!
Hasiba, I quote the imperial college study I forwarded earlier
“ It showed that a single dose of Pfizer/BioNTech’s RNA vaccine resulted in a significantly enhanced immune response against the virus, compared to a single dose in those without prior infection.
The enhanced response was at least an order of magnitude greater than after a conventional two-dose vaccine schedule in a previously uninfected individual.”
Long Covid is just a clinical description and I’m not so sure if it’s clearly defined - it’s an evolving phenomena. It doesn’t tell you what happens at cellular level. The above is probably relevant.
https://www.gov.uk/government/news/latest-findings-from-antibody-surveillance-study-published
https://www.google.co.uk/amp/s/www.imperial.ac.uk/news/215793/single-dose-vaccine-acts-booster-those/amp/
Hasiba, I hope that data is buried somewhere within these 2 studies - not the Scottish study. Coverage was on BBC WS yesterday. Lots of new data to help our understanding of the immune response to Covid pre- and post- vaccination. Any evidence of long term immunity will be the bigger success of the vaccination programme.
Our highly differentiated approach to the existing vaccines should attract Big Pharma partners.